Oxford Global: NextGen Biomed 2026
Conference dates: March 24-25, 2026
Stand: 87
Location: Queen Elizabeth II Centre, London
Poster session
Poster Title: Strategies for Scalable and Sensitive Determination of High Affinity and Slow Dissociating Binding Interaction Kinetics in Antibody Discovery
Presenter: Judicael Parisot, Ph.D., Applications Science Team Lead, Carterra
Abstract: Monoclonal antibodies are powerful tools for therapeutic and diagnostic applications and binding kinetics is an important element of the potency and efficacy of these molecules. Many antibodies and optimized therapeutics show very high affinities with stable dissociation kinetics, and these high affinity interactions represent a challenge for accurate measurement using real time SPR binding studies, as slow dissociation yields minimal signal change over typical time courses. This poster explores two effective strategies using HT-SPR to measure slow dissociation of many interactions in parallel and with high sensitivity. The most sensitive and simple approach is the use of a chase injection to measure surface occupancy after a long dissociation period. The other is the use of both short and long dissociation times, which can enable an extended dissociation phase without excessively extending the overall length of an experiment. Both these approaches can be implemented at scale for the screening and characterization of hundreds to thousands of high affinity interactions using Carterra HT-SPR platforms.
Speaking session
Title: Redefining High-Throughput SPR: The Carterra Vega Platform
Presenter: Judicael Parisot, Ph.D., Applications Science Team Lead, Carterra
Date and Time: Tuesday, Mar. 24, 2026 | 15:10
Abstract: Carterra transformed high-throughput surface plasmon resonance (SPR)–based antibody discovery with the launch of its one-on-384 array LSA platform in 2018. The newly developed Vega platform substantially increases analyte throughput to 48 channels, with each channel containing two ligand spots and a reference. This presentation will introduce Carterra Vega and demonstrate its functionality through two case studies. The first case study describes the use of Vega’s 48-channel injections to simultaneously characterize binding kinetics and specificity of 48 monovalent antibodies against human and cynomolgus forms of a dimeric receptor. The second case study highlights high-throughput screening of a small-molecule library against a target and a counter-target, with rapid confirmation of hit compounds through titration experiments.